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Miyawaki	 et	 al.	 identify	 the	 most	 primitive	 progenitor	 cell	 population	 that	 only	 makes	
megakaryocytes	 and	 platelets	 in	 adult	 humans,	 and	 show	 it	 is	 expanded	 in	
myeloproliferative	 neoplasms	 such	 as	 essential	 thrombocythemia	 (ET)	 1.	 Around	 1011	
platelets	 are	 produced	 on	 a	 daily	 basis	 in	 humans	 but	 their	 exact	 journey	 from	
undifferentiated	hematopoietic	 stem	cells	 (HSCs)	 is	 still	highly	debated.	Platelets	have	 the	
shortest	half-life	of	all	blood	components,	are	rapidly	recruited	when	injury	occurs,	yet	have	
long	been	thought	to	be	among	the	cell	types	to	be	specified	the	furthest	from	the	HSCs	in	
the	 hematopoietic	 hierarchy.	 For	 several	 decades,	 it	 was	 understood	 that	 differentiation	
proceeds	 by	 a	 series	 of	 binary	 fates	 choices,	 in	 particular	 with	 a	 Common	 Myeloid	
Progenitor	 (CMP)	 downstream	 of	 HSCs	 that	 would	 give	 rise	 to	 a	 restricted	 myeloid	
progenitor	(GMP),	and	to	a	Megakaryocyte-Erythrocyte	Progenitor	(MEP).	Only	downstream	
of	 MEPs	 would	 unilineage	 megakaryocyte	 and	 unilineage	 erythrocyte	 progenitors	 arise.	
Recently	 though,	 several	 groups	 have	 reported	 that	 megakaryocytes	 and	 platelets	
production	 may	 not	 follow	 this	 strict	 hierarchical	 branching	 path.	 Instead,	 committed	
megakaryocyte	 precursors	 could	 be	 found	much	 earlier,	 either	within	 the	HSC	 2–4	 	 or	 the	
multipotent	progenitor	compartment	5.		An	early	precursor	that	exclusively	produces	human	
megakaryocytes	in	humans	had	however	never	been	described	to	date.	
	
Here	Miyawaki	et	al.	 focused	on	the	human	myeloid	progenitor	compartment,	and	used	a	
combination	 of	 single	 cell	 qPCR	 and	 in	 vitro	 differentiation	 assays	 to	 identify	 a	
homogeneous	population	of	cells	which	fate	is	restricted	to	megakaryopoiesis.	For	this,	they	
investigated	 single	 cells	 from	 the	 classically	 defined	 CMP,	 MEP	 and	 GMP	 compartments	
found	in	the	CD34+	CD38+	fraction	of	human	bone	marrow.	The	only	cells	that	were	uniquely	
committed	to	produce	megakaryocytes	in	vitro	and	in	vivo	(termed	MegPs)	were	found	as	a	
distinct	subpopulation	within	the	CMP	compartment.	This	small	population	(approximately	
8%	 of	 CMPs)	 was	 marked	 by	 CD41	 cell	 surface	 expression	 and	 characterized	 by	 high	
expression	of	 the	megakaryocyte	master	 transcription	 factor	Fli1.	 In	contrast,	only	a	small	
percentage	of	 single	MEPs	would	give	 rise	 to	small	megakaryocytic	colonies.	 Interestingly,	
Miyawaki	et	al.	showed	that	the	MegP	population	was	found	both	 in	umbilical	cord	blood	
and	adult	bone	marrow,	suggesting	that	 its	presence	is	maintained	over	a	human	lifetime.	
Of	note,	CD41-	CMPs	could	also	produce	robust	platelet	engraftment	in	vivo	but	always	in	
combination	with	myeloid	and	erythroid	cells.	The	key	message	from	this	work	is	that	fate	
restriction	 to	 megakaryocyte	 production	 predominantly	 occurs	 at	 the	 level	 of	 the	 CD41+	
MegP	population	in	human	bone	marrow.	
	
A	 handful	 of	 recent	 studies	 used	 single	 cell	 tools	 to	 identify	 when	 erythroid	 and	
megakaryocyte	potential	separate	in	humans.	Two	of	these	have	reported	the	existence	of	
small	 pockets	 of	 bilineage	 erythroid-megakaryocyte	 progenitor	 cells	within	 the	 CMP5	 and	
MEP	populations	5,6,	but	no	unilineage	MegPs.	The	discrepancy	between	these	studies	and	
that	of	Miyawaki	et	al.	is	likely	to	be	largely	technical,	as	different	sorting	strategies	and/or	
cellular	sources	were	employed.	In	addition,	genome-wide	single	cell	RNA-seq	of	the	whole	
bone	marrow	CD34+	 compartment	 showed	 strong	unilineage	megakaryocyte	priming	 in	 a	
fraction	 of	 the	 CD34+	 CD38+	 compartment,	 and	 the	 existence	 of	 a	 subpopulation	 of	
multipotent	progenitors	with	high	 contribution	 to	megakaryopoiesis	 7.	What	emerges	 is	 a	
picture	in	which,	at	the	single	cell	level,	the	classically	defined	CMP	and	MEP	are	much	more	
heterogeneous	than	originally	thought.	Specifically,	it	seems	that	the	proportion	of	cells	that	
have	capacity	to	differentiate	into	more	than	one	mature	blood	cell	type	is	very	likely	low,	
especially	in	adults.	Similar	conclusions	were	recently	reached	in	mouse	models	8,9.		
	
Two	questions	that	remain	open	are:	how	are	MegPs	specified	at	the	molecular	level?	and	
which	cell	is	their	direct	parent?	The	authors	demonstrated	that	CD41-	CMPs	could	give	rise	
to	CD41+	CMPs	 in	vitro,	but	whether	 this	 is	 the	main	 route	of	MegP	production	 in	vivo	at	
homeostasis	or	following	injury	remains	to	be	clarified.	This	may	be	difficult	to	assess	with	
the	 current	 tools	 directly	 in	 human	 cells,	 but,	 as	 studies	 in	 mice	 have	 suggested	 that	 in	
certain	 conditions	 HSCs	 exclusively	 give	 rise	 to	 platelets	 2,4	 and	 that	 megakaryocyte-
restricted	progenitors	reside	in	the	compartment	that	is	commonly	used	to	purify	HSCs	3,10,	
it	 would	 be	 interesting	 to	 know	 if	 the	 MegP	 is	 an	 obligatory	 cellular	 step	 during	
megakaryopoiesis.		
	
Another	 important	 finding	 of	 this	 study	 is	 that	 MegPs	 isolated	 from	 patients	 with	 JAK2	
V617F	mutant	ET	are	expanded	and	tend	to	produce	more	megakaryocytes	than	those	from	
healthy	controls.	Direct	 comparison	of	 the	 function	of	 JAK2	V617F	mutated	and	wild-type	
MegPs	 and	 their	 progenitors	 within	 the	 same	 patient	 was	 not	 carried	 out.	 However	 one	
implication	 of	 these	 data	 is	 that	 mutations	 such	 as	 JAK2	 V617F,	 recurrent	 in	
myeloproliferative	 neoplasms	 or	 in	 clonal	 hematopoiesis	 of	 indeterminate	 potential,	 can	
have	 strong	effects	not	only	on	 the	HSC	compartment	but	also	on	 specific	progenitor	 cell	
types.	In	the	case	of	expansion	of	MegPs	in	ET,	future	studies	will	have	to	address	how	much	
this	 expansion	 accounts	 for	 ET	 pathology	 and	 identify	 which	 molecular	 mechanisms	
downstream	of	the	JAK2	V617F	mutation	drive	this	expansion	specifically	in	patients	with	ET	
and	not	in	patients	with	other	types	of	myeloproliferative	neoplasms.	A	deep	understanding	
of	the	normal	routes	of	commitment,	their	fluctuations	over	a	human	lifetime	and	how	they	
are	 skewed	 in	 malignancy,	 will	 be	 highly	 informative	 for	 how	 we	 should	 treat	 blood	
diseases.			
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FIGURE:	
Please	use	Figure	7	of	Miyawaki	et	al.		
	
CAPTION:		
Model	of	megakaryopoiesis	proposed	by	Miyawaki	et	al..	Megakaryocyte	production	in	
human	bone	marrow	proceeds	through	a	unilineage	MegP	progenitor	that	can	be	purified	
within	the	classic	CMP	compartment	as	CD34+	CD38+	CD45RA-	IL-3Rαdim	CD41+.	In	patients	
with	JAK2	V617F	mutated	essential	thrombocythemia,	the	MegP	population	is	expanded	
and	may	contribute	to	disease	pathology.		
	
	 	
	
